Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY2584702 Reference Formulation
LY2584702 · 1 trial · 1 indication
A clinically significant effect was any event that was a dose-limiting toxicity event (DLT). DLT was defined as an adverse event related to LY2584702 during Cycle 1 (Day 1 to Day 30) that fulfills any one of the following criteria; Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 non-hematological toxicity; platelet count \<50.0 x 10\^9/Liter (L) with bleeding; CTCAE Grade 4 platelet count decreased; neutrophil count \<0.5 x 10\^9/L lasting for 5 days or longer; any febrile neutropenia; CTCAE Grade 4 anemia; participant risk due to increasing toxicity.
| Arm | Type | Description |
|---|---|---|
| LY2584702 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LY2584702 | DRUG | Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle. Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met. |
Inclusion Criteria: * Have histological or cytological evidence of a diagnosis of advanced and/or metastatic cancer (solid tumors) that is refractory to standard therapy and/or therapies known to provide clinical benefit, or for which no standard therapy exists. * Have the presence of disease amena...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LY2584702 is an investigational small molecule developed by Eli Lilly and Company for the treatment of cancer. It is a kinase inhibitor that has been studied in solid tumors. It is also referred to as LY2584702 Reference Formulation. The compound is in Phase 1 clinical development and has not been approved for any indication.
LY2584702 targets RPS6KB1, also known as p70S6 kinase, an enzyme involved in cell growth and protein synthesis signaling. LY2584702 acts as an inhibitor of this target. Inhibiting RPS6KB1 is the proposed mechanism by which the compound is intended to affect tumor cell signaling in cancer.
LY2584702 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating the compound in oncology. The drug remains an investigational agent and is not a marketed product.
LY2584702 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 program has been conducted in patients with solid tumors, and the single listed trial has completed.
LY2584702 has been evaluated in one Phase 1 trial, NCT01241461, titled A Study of LY2584702 in Solid Tumors. That trial enrolled 9 participants in Japan, included patients aged 20 years and older of any sex, and is now completed. It was an uncontrolled study without randomization or blinding.
Yes. LY2584702 Reference Formulation is an alternative name for LY2584702, the small molecule RPS6KB1 inhibitor developed by Eli Lilly and Company. Both names refer to the same investigational oncology compound. Searches for either name point to the same Phase 1 solid tumor program.